Tesofensine Peptide Therapy
Benefits, Side Effects, Cost & Protocols
Tesofensine is a novel triple monoamine reuptake inhibitor (serotonin, norepinephrine, dopamine) originally developed for neurodegenerative diseases that demonstrated significant weight loss effects in clinical trials. It reduces appetite and increases metabolic rate through central nervous system mechanisms.
Clinically Reviewed
Reviewed by Alex Evans, PharmD, MBA · Updated May 2026
Evidence-Based
Sourced from FDA, PubMed & ClinicalTrials.gov · View sources
Who Is Tesofensine Best For?
How Tesofensine Works
Inhibits reuptake of serotonin, norepinephrine, and dopamine, leading to reduced appetite, increased satiety, and potentially enhanced fat metabolism. Different mechanism than GLP-1 agonists.
Tesofensine FAQ
What is TESOFENSINE?
Tesofensine is a triple monoamine reuptake inhibitor originally developed for Parkinson's and Alzheimer's disease, now researched primarily for its significant weight loss effects. It affects serotonin, norepinephrine, and dopamine.
How does TESOFENSINE work?
Inhibits reuptake of serotonin, norepinephrine, and dopamine, leading to reduced appetite, increased satiety, and potentially enhanced fat metabolism. Different mechanism than GLP-1 agonists.
Is TESOFENSINE legal to buy?
TESOFENSINE is sold as a research chemical for laboratory use only. It is not approved for human use by the FDA. Regulations vary by jurisdiction.
Where can I buy TESOFENSINE?
TESOFENSINE is available as a research compound from verified online vendors. Always verify third-party testing before purchasing.
What category does TESOFENSINE belong to?
TESOFENSINE is primarily classified as a weight loss & metabolic peptide. Peptides researched for their effects on weight management, fat metabolism, appetite regulation, and metabolic enhancement. This category includes GLP-1 agonists, dual/triple agonists, and other metabolic peptides.
What are the research benefits of TESOFENSINE?
TESOFENSINE has been studied for: Significant weight loss potential, Appetite suppression, Increased satiety, Potential cognitive benefits. Triple reuptake inhibitor; showed 10%+ weight loss in Phase 2 trials. Not yet FDA approved.
Key Studies
55 total on PubMed0Quantitative pharmacology approach in Alzheimer's disease: efficacy modeling of early clinical data to predict clinical outcome of tesofensine
Lehr T, Staab A, Trommeshauser D et al
AAPS JPhase 2
PK/PD modeling predicted negative outcome of tesofensine phase IIb trial in Alzheimer's disease.
PK/PD modeling predicted negative outcome of tesofensine phase IIb trial in Alzheimer's disease
Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease
Hauser RA, Salin L, Juhel N et al
Mov Disord · Mov DisordPhase 2
NS 2330 did not provide significantly greater benefit than placebo in early Parkinson's disease.
NS 2330 did not provide significantly greater benefit than placebo in early Parkinson's disease
[The effect of tesofensine on body weight and body composition in obese subjects--secondary publication]
Nielsen AL, Larsen TM, Madsbad S et al
Ugeskr Laeger · Ugeskr LaegerPhase 2
Tesofensine 0.5-1.0 mg produced weight loss 9-11% greater than placebo.
Tesofensine 0.5-1.0 mg produced weight loss 9-11% greater than placebo
Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial
Tesofensine Compound Data
Tesofensine News
Athlete Advisory: What’s New on the 2025 WADA Prohibited List? - usada.org
usada.org · 19 months ago
Tesofensine For Sale: 3 Legit Places To Buy Online - Mid-day
Mid-day · 23 months ago
News aggregated via Google News. Inclusion does not imply endorsement.
Ready to explore Tesofensine with a provider?
Take our 2-minute quiz to get matched with a board-certified provider specializing in Tesofensine.
Take the Quiz →